At a glance
Effects
- Bronchial epithelial repair: In laboratory and preclinical models, Bronchogen stimulates reparative processes in bronchial epithelial cell cultures, supporting the regenerative capacity of airway lining cells [4][5].
- Anti-inflammatory signalling: Pro-inflammatory cytokine patterns shift toward reduced inflammatory signalling in cell-culture studies, potentially supporting management of chronic bronchitis and COPD [7].
- Mucociliary & immune support: Research models show improved ciliary function, increased surfactant protein B, and elevated secretory IgA — the frontline mucosal antibody [6][7].
- Gene-expression normalisation: Expression increases of key respiratory genes (NKX2-1, FOXA1/2, SCGB1A1/3A2) ranging from 1.5× to 15× baseline have been reported in bronchial cell culture studies [5].
- Age-related lung support: Khavinson-group research reports improvements in respiratory function parameters in elderly patients, and the bioregulator framework proposes restoration of youthful gene-expression patterns [8][3].
Tetrapeptide bioregulator (Khavinson peptide)
Ala-Glu-Asp-Leu (AEDL); MW 446.45 g/mol, C₁₈H₃₀N₄O₉
Oral (enteric-coated capsule) or subcutaneous injection
Not formally established; ultrashort peptides typically clear in seconds–minutes [9]
Not FDA-approved; sold as supplement / research compound [12]
About Bronchogen
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Bronchogen (also designated T-33 or AEDL) is a synthetic tetrapeptide bioregulator — four amino acids in the sequence Ala-Glu-Asp-Leu — belonging to the Khavinson peptide family and specifically developed to support and restore function of the bronchi and lung tissue [1][2]. It is used in the research and wellness context as a broncho-pulmonary supplement, with proposed applications in chronic bronchitis, COPD, and age-related respiratory decline [3].
How it works
Bronchogen's tetrapeptide structure allows it to penetrate both cellular and nuclear membranes, where it is proposed to interact with DNA at the guanine N7 site in the major groove without visibly distorting the double helix [4]. This interaction is thought to increase DNA thermostability in bronchial cells, modulate chromatin structure, and upregulate gene expression in bronchial epithelial tissue — particularly genes such as NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2, which govern lung cell identity, surfactant production, and epithelial differentiation [5][6]. The net effect, in laboratory models, is normalisation of protein synthesis in bronchopulmonary cells, promotion of mucociliary clearance, support for secretory IgA production, and downregulation of pro-inflammatory cytokines [7]. Because the epigenetic changes are proposed to outlast the peptide's short circulating lifespan, effects may persist well after a dosing cycle ends [8].
Risks & side effects
Most important: Formal human safety and pharmacokinetic data for Bronchogen are extremely limited — most evidence originates from Russian preclinical and in vitro studies, and no double-blind clinical trials exist in English-language literature [8][9]. Because robust human safety data are unavailable, the true risk profile is unknown; this substance should not be used without medical supervision, particularly in individuals with active lung disease [1].
Common
Serious
- Unknown interaction profile with inhaled corticosteroids, bronchodilators, or immunosuppressants — no clinical data exist [9]
- Risk of masking worsening respiratory disease if used instead of established treatment [1]
- Oral bioavailability uncertain: gastrointestinal proteases may degrade the tetrapeptide before meaningful absorption, making dosing unpredictable [9]
Safety & harm reduction
- Manufacturer-aligned oral protocols: typically 10–20 mg daily in capsule form for 10–20 day cycles [13][14]
- Research injectable protocols: approximately 200 mcg daily subcutaneous, 28–30 day cycle (community-reported; not clinically validated) [15]
- Oral bioavailability is lower than injectable; higher oral doses are used to compensate, but direct comparison data are limited [11]
- Store oral capsules at room temperature; store lyophilised injectable powder refrigerated at 2–8 °C; use reconstituted solution within 20 days [10]
- Always source from suppliers providing third-party HPLC/mass-spectrometry certificate of analysis confirming ≥99% purity [11]
- Consult a qualified healthcare provider before initiating any protocol [1]
Dosage context
No formal human clinical dosing has been established. Community and vendor-reported oral doses are 10–20 mg daily in cycled protocols of 10–20 days [13][14]. Research injectable protocols commonly cite 200 mcg/day subcutaneous for 28–30 days [15]. These figures are extrapolations from preclinical research — they are NOT prescriptions and significant uncertainty exists regarding bioavailability, particularly via the oral route [9]. Consult a qualified healthcare provider before use.
Sources
- 1.Exploring Peptides — Bronchogen overview
- 2.Limitless Biotech — Bronchogen product & mechanism
- 3.E-Peptide — Bronchogen supplement page
- 4.CorePeptides — Bronchogen bronchial cell studies
- 5.SeekPeptides — Bronchogen complete guide (gene targets)
- 6.BioLongevity Labs — Bronchogen cellular regeneration research
- 7.CalcMyPeptide — Bronchogen dosing guide & mechanism
- 8.Peptide Database — Bronchogen overview & epigenetic mechanism
- 9.PeptideInsight — Bronchogen pharmacokinetics & safety
- 10.Peptide Assistant — Bronchogen side effects & storage
- 11.PeptideDeck — Bronchogen complete guide (purity & bioavailability)
- 12.WolveStack — Bronchogen dosage guide
- 13.Peptide Products — Bronchogen supplement page (oral protocol)
- 14.PeptiBase — Bronchogen research & dose review 2026
- 15.Jay Campbell — Bronchogen injectable dosage & benefits
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.